Omega Therapeutics, Inc. (OMGA)
NASDAQ: OMGA · Real-Time Price · USD
0.790
+0.030 (3.97%)
At close: Nov 20, 2024, 4:00 PM
0.810
+0.020 (2.56%)
Pre-market: Nov 21, 2024, 4:11 AM EST
Omega Therapeutics Revenue
Omega Therapeutics had revenue of $2.61M in the quarter ending September 30, 2024, with 214.32% growth. This brings the company's revenue in the last twelve months to $8.10M, up 185.04% year-over-year. In the year 2023, Omega Therapeutics had annual revenue of $3.09M with 49.25% growth.
Revenue (ttm)
$8.10M
Revenue Growth
+185.04%
P/S Ratio
5.38
Revenue / Employee
$86,117
Employees
94
Market Cap
43.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.09M | 1.02M | 49.25% |
Dec 31, 2022 | 2.07M | 1.93M | 1,339.58% |
Dec 31, 2021 | 144.00K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
NeueHealth | 996.89M |
Fortress Biotech | 81.50M |
Accelerate Diagnostics | 11.91M |
Verrica Pharmaceuticals | 9.21M |
LAVA Therapeutics | 7.40M |
Nexalin Technology | 162.08K |
OMGA News
- 5 weeks ago - Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings - GlobeNewsWire
- 2 months ago - Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications - GlobeNewsWire
- 3 months ago - Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - GlobeNewsWire
- 3 months ago - Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 5 months ago - Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors - GlobeNewsWire
- 6 months ago - Omega Therapeutics To Participate In Two Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer - GlobeNewsWire
- 7 months ago - Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers - GlobeNewsWire